247 related articles for article (PubMed ID: 19615901)
1. The P1N-isopropyl motif bearing hydroxyethylene dipeptide isostere analogues of aliskiren are in vitro potent inhibitors of the human aspartyl protease renin.
Yamaguchi Y; Menear K; Cohen NC; Mah R; Cumin F; Schnell C; Wood JM; Maibaum J
Bioorg Med Chem Lett; 2009 Aug; 19(16):4863-7. PubMed ID: 19615901
[TBL] [Abstract][Full Text] [Related]
2. Structural modification of the P2' position of 2,7-dialkyl-substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamides: the discovery of aliskiren, a potent nonpeptide human renin inhibitor active after once daily dosing in marmosets.
Maibaum J; Stutz S; Göschke R; Rigollier P; Yamaguchi Y; Cumin F; Rahuel J; Baum HP; Cohen NC; Schnell CR; Fuhrer W; Gruetter MG; Schilling W; Wood JM
J Med Chem; 2007 Oct; 50(20):4832-44. PubMed ID: 17824680
[TBL] [Abstract][Full Text] [Related]
3. Total synthesis of "aliskiren": the first Renin inhibitor in clinical practice for hypertension.
Hanessian S; Guesné S; Chénard E
Org Lett; 2010 Apr; 12(8):1816-9. PubMed ID: 20235519
[TBL] [Abstract][Full Text] [Related]
4. Formal total synthesis of the potent renin inhibitor aliskiren: application of a SmI2-promoted acyl-like radical coupling.
Lindsay KB; Skrydstrup T
J Org Chem; 2006 Jun; 71(13):4766-77. PubMed ID: 16776501
[TBL] [Abstract][Full Text] [Related]
5. Novel 2,7-dialkyl-substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamide transition state peptidomimetics are potent and orally active inhibitors of human renin.
Göschke R; Stutz S; Rasetti V; Cohen NC; Rahuel J; Rigollier P; Baum HP; Forgiarini P; Schnell CR; Wagner T; Gruetter MG; Fuhrer W; Schilling W; Cumin F; Wood JM; Maibaum J
J Med Chem; 2007 Oct; 50(20):4818-31. PubMed ID: 17824679
[TBL] [Abstract][Full Text] [Related]
6. Aliskiren: clinical experience and future perspectives of renin inhibition.
Sureshkumar KK; Vasudevan S; Marcus RJ; Hussain SM; McGill RL
Expert Opin Pharmacother; 2008 Apr; 9(5):825-37. PubMed ID: 18345958
[TBL] [Abstract][Full Text] [Related]
7. Conformational analysis of aliskiren, a potent renin inhibitor, using high-resolution nuclear magnetic resonance and molecular dynamics simulations.
Matsoukas MT; Zoumpoulakis P; Tselios T
J Chem Inf Model; 2011 Sep; 51(9):2386-97. PubMed ID: 21777001
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of hydroxyethylene-based peptidomimetic inhibitors of human beta-secretase.
Hom RK; Gailunas AF; Mamo S; Fang LY; Tung JS; Walker DE; Davis D; Thorsett ED; Jewett NE; Moon JB; John V
J Med Chem; 2004 Jan; 47(1):158-64. PubMed ID: 14695829
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of a Gln-Phe hydroxy-ethylene dipeptide isostere.
Haug BE; Rich DH
Org Lett; 2004 Dec; 6(25):4783-6. PubMed ID: 15575685
[TBL] [Abstract][Full Text] [Related]
10. NEW RENIN INHIBITORS - STABILITY AND ACTIVITY DETERMINATION. PART IV.
Marszalek D; Goldnik A; Winiecka I; Jaworsk P; Mazurek Aleksander P
Acta Pol Pharm; 2017 Mar; 74(2):393-399. PubMed ID: 29624244
[TBL] [Abstract][Full Text] [Related]
11. Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin.
Rahuel J; Rasetti V; Maibaum J; Rüeger H; Göschke R; Cohen NC; Stutz S; Cumin F; Fuhrer W; Wood JM; Grütter MG
Chem Biol; 2000 Jul; 7(7):493-504. PubMed ID: 10903938
[TBL] [Abstract][Full Text] [Related]
12. Formal total synthesis of aliskiren.
Peters BK; Liu J; Margarita C; Andersson PG
Chemistry; 2015 May; 21(19):7292-6. PubMed ID: 25783891
[TBL] [Abstract][Full Text] [Related]
13. Design and optimization of renin inhibitors: Orally bioavailable alkyl amines.
Tice CM; Xu Z; Yuan J; Simpson RD; Cacatian ST; Flaherty PT; Zhao W; Guo J; Ishchenko A; Singh SB; Wu Z; Scott BB; Bukhtiyarov Y; Berbaum J; Mason J; Panemangalore R; Cappiello MG; Müller D; Harrison RK; McGeehan GM; Dillard LW; Baldwin JJ; Claremon DA
Bioorg Med Chem Lett; 2009 Jul; 19(13):3541-5. PubMed ID: 19457666
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and evaluation of Leu*Ala hydroxyethylene-based non-peptide beta-secretase (BACE) inhibitors.
Xiao K; Li X; Li J; Ma L; Hu B; Yu H; Fu Y; Wang R; Ma Z; Qiu B; Li J; Hu D; Wang X; Shen J
Bioorg Med Chem; 2006 Jul; 14(13):4535-51. PubMed ID: 16510290
[TBL] [Abstract][Full Text] [Related]
15. Structure-based optimization of potent 4- and 6-azaindole-3-carboxamides as renin inhibitors.
Scheiper B; Matter H; Steinhagen H; Böcskei Z; Fleury V; McCort G
Bioorg Med Chem Lett; 2011 Sep; 21(18):5480-6. PubMed ID: 21840218
[TBL] [Abstract][Full Text] [Related]
16. Structure-based drug design and the discovery of aliskiren (Tekturna): perseverance and creativity to overcome a R&D pipeline challenge.
Cohen NC
Chem Biol Drug Des; 2007 Dec; 70(6):557-65. PubMed ID: 17999663
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and SAR of hydroxyethylamine based phenylcarboxyamides as inhibitors of BACE.
Wu YJ; Zhang Y; Good AC; Burton CR; Toyn JH; Albright CF; Macor JE; Thompson LA
Bioorg Med Chem Lett; 2009 May; 19(10):2654-60. PubMed ID: 19375914
[TBL] [Abstract][Full Text] [Related]
18. The discovery and preparation of disubstituted novel amino-aryl-piperidine-based renin inhibitors.
Cody WL; Holsworth DD; Powell NA; Jalaie M; Zhang E; Wang W; Samas B; Bryant J; Ostroski R; Ryan MJ; Edmunds JJ
Bioorg Med Chem; 2005 Jan; 13(1):59-68. PubMed ID: 15582452
[TBL] [Abstract][Full Text] [Related]
19. Effects of aliskiren, a renin inhibitor, on biomarkers of platelet activity, coagulation and fibrinolysis in subjects with multiple risk factors for vascular disease.
Serebruany VL; Malinin A; Barsness G; Vahabi J; Atar D
J Hum Hypertens; 2008 May; 22(5):303-10. PubMed ID: 18273042
[TBL] [Abstract][Full Text] [Related]
20. Cardio-renal protection with aliskiren, a direct renin inhibitor, in the ASPIRE HIGHER program.
Lee HY; Oh BH
Expert Rev Cardiovasc Ther; 2009 Mar; 7(3):251-7. PubMed ID: 19296761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
